Granite Bio AG, a clinical-stage biotechnology company focused on inflammatory and autoimmune diseases, has launched with $100 million in combined Series A and B funding. The Series A round raised $30 million, led by Founding Investors Versant Ventures and Novartis Venture Fund, while the $70 million Series B was led by Forbion and Sanofi Ventures. The company is advancing two first-in-class antibodies: GRT-001, which targets pro-inflammatory monocytes and is currently in Phase 1a trials, and GRT-002, an interleukin-3 inhibitor in preclinical development aimed at allergy and inflammation. GRT-001 showed promising safety and efficacy in non-human primates and is expected to enter Phase 1b trials in inflammatory bowel disease later this year.
Both lead candidates were developed in collaboration with Versant’s Ridgeline Discovery Engine and Stem from Research by Professor Matthias Mack of the University of Regensburg. Patrick Loustau, President and CEO, stated, “With the support of an exceptional investor syndicate and a world-class team, we are advancing a pipeline of first-in-class therapies with the potential to transform patient outcomes. I look forward to working with the management team to deliver groundbreaking treatments that address the urgent unmet needs in immunology and beyond." With backing from top life science Investors and a team of experienced Executives, Granite Bio plans to bring new therapies to patients with chronic inflammatory and fibrotic conditions.
